The generation of therapeutic medications using live cells is the way forward for pharmaceutical development. Because of their secretory function, distinct homing effects, unique therapeutic potential, and ex vivo expandability, cell-based therapies (e.g., CAR-T, TCR-T) have emerged as appealing treatments for advanced therapeutic techniques. Still, these approaches encounter a number of difficulties: There are four possible outcomes: a) endogenous gene disruption; b) using viral gene transfer; c) subjecting cells to severe environments; and d) permanent genetic change.
For more: cell FucT conjugate
One component that is essential to a live body is glycan. Nearly all cells and their surfaces are heavily modified with mono- and oligosaccharides. A range of glycosyltransferases catalyze them.
Our CellFaceTM conjugate technology, which is based on a class of universal glycosyls that are expressed on nearly all cell surfaces and is supported by years of experience and expertise in glycan biochemistry, enables the broad applicability of our cell surface modification technology.
Glycosyltransferases are glycan-processing enzymes that attach themselves to particular substrates by identifying various mono- and oligosaccharide derivatives (conjugate donors) with activated groups. Glycosyltransferase’s substrate selectivity and sugar donor compatibility allow for the functional investigation and adjustment of certain glycosylation alterations in vivo.
FucT is a fucose transferase that attaches fucose covalently to the ends of glycosyl fragments on the cell surface by using GDP-Fucose as a sugar donor. The enzyme exhibits excellent compatibility with the donor, and the introduction of a sterically hindered group has no effect on the enzyme’s catalytic performance. Given that glycocalyx is present on the surface of many cells, our method may be an effective means of securing big molecules to the cell surface.